Blenrep, a cancer drug from GSK (US), significantly reduced the risk of death and is poised to regain regulatory approval.
Thursday, Nov 14, 2024 3:51 am ET
1min read British pharmaceutical giant GlaxoSmithKline (GSK.US) said its blood cancer drug, when used in combination with another cancer treatment, significantly reduced the risk of death for cancer patients, further improving the prospects of bringing back its cancer drug Blenrep to the market after it was withdrawn by the FDA and European Medicines Agency.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.